Fresenius Kabi Oncology has withdrawn its revocation petitions against patents for cancer drugs owned by US pharma major Pfizer and its subsidiaries, citing lack of business interest. After fighting a patent battle over four patents and two products, Fresenius Kabi Oncology, the Indian arm of Germany-based Fresenius Kabi, informed the IPAB it has lost business interest in the molecules and hence wanted to withdraw the revocation petitions against Pfizer. The patent dispute and the subsequent filing of the revocation pleas had been mainly on two products, Crizotinib, branded as Xalkori, and Axitinib, branded as Inlyta.